Zobrazeno 1 - 10
of 799
pro vyhledávání: '"M Walshe"'
Autor:
Lynda M. McSorley, Mehala Tharmabala, Fathiya Al Rahbi, Fergus Keane, Denis Evoy, James G. Geraghty, Jane Rothwell, Damian P. McCartan, Megan Greally, Miriam O’Connor, Deirdre O’Mahony, Maccon Keane, Michael John Kennedy, Seamus O’Reilly, Steve J. Millen, John P. Crown, Catherine M. Kelly, Ruth S. Prichard, Cecily M. Quinn, Janice M. Walshe
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1302-1310 (2024)
Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational stu
Externí odkaz:
https://doaj.org/article/c7e991104cdb4851bf2dfdfc09b20e5d
Autor:
Nicola Cosgrove, Alex J. Eustace, Peter O’Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blümel, Darren O’Connor, Sudipto Das, Małgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments i
Externí odkaz:
https://doaj.org/article/2aa94f4a6ce8446ea48464a6049912d0
Autor:
Fionán Donohoe, Yvonne O’Meara, Aidin Roberts, Louise Comerford, Ivaila Valcheva, Una Kearns, Marie Galligan, Michaela J. Higgins, Alasdair L. Henry, Catherine M. Kelly, Janice M. Walshe, Martha Hickey, Donal J. Brennan
Publikováno v:
Cancers, Vol 16, Iss 6, p 1127 (2024)
Background: Vasomotor symptoms (VMSs) associated with menopause represent a significant challenge for many patients after cancer treatment, particularly if conventional menopausal hormone therapy (MHT) is contraindicated. Methods: The Menopause after
Externí odkaz:
https://doaj.org/article/7fc676ad7bc142d4842c5f7424a7718b
Autor:
Hope S. Rugo, Seock-Ah Im, Anil A. Joy, Yaroslav Shparyk, Janice M. Walshe, Bethany Sleckman, Sherene Loi, Kathy Puyana Theall, Sindy Kim, Xin Huang, Eustratios Bananis, Reshma Mahtani, Richard S. Finn, Véronique Diéras
Publikováno v:
Breast, Vol 66, Iss , Pp 324-331 (2022)
Background: Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in the overall population of patients wit
Externí odkaz:
https://doaj.org/article/a722b0955acd4472b01e048a4c0096ba
Autor:
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Jr., Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice M. Walshe, Manuel Ruíz Borrego, Halle CF. Moore, Christobel Saunders, Fatima Cardoso, Snezana Susnjar, Vesna Bjelic-Radisic, Karen L. Smith, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani
Publikováno v:
Breast, Vol 59, Iss , Pp 327-338 (2021)
Background: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5–10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the imp
Externí odkaz:
https://doaj.org/article/e32b73f6538741fb915cc74aa4bb1fbe
Autor:
Karen Gelmon, Janice M. Walshe, Reshma Mahtani, Anil A. Joy, Meghan Karuturi, Patrick Neven, Dongrui Ray Lu, Sindy Kim, Patrick Schnell, Eustratios Bananis, Lee Schwartzberg
Publikováno v:
Breast, Vol 59, Iss , Pp 321-326 (2021)
Objective: In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–
Externí odkaz:
https://doaj.org/article/e1de20316af7412ea231ee450ee37491
Autor:
Fionán Donohoe, Yvonne O'Meara, Aidin Roberts, Louise Comerford, Catherine M. Kelly, Janice M. Walshe, Michelle Peate, Martha Hickey, Donal J. Brennan
Publikováno v:
Contemporary Clinical Trials Communications, Vol 24, Iss , Pp 100865- (2021)
Aims: This study will aim to assess if a composite intervention which involves a specific evidence-based intervention for management of insomnia and non-hormonal pharmacotherapy to manage vasomotor symptoms (VMS) of menopause can improve quality of l
Externí odkaz:
https://doaj.org/article/921b7a89bb2646ac8d51b7c7875e52c9
Autor:
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B. Sætersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E. Lee, Janice M. Walshe, Manuel Ruíz-Borrego, Halle C.F. Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L. Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Roswitha Kammler, Sarra El-Abed, Giuseppe Viale, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani
Publikováno v:
New England journal of medicine, 388(18), 1645-1656. Massachussetts Medical Society
Background Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Methods We conducted a single-group trial in which we
Autor:
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, James L Wade, Edward C McCarron, Sandra M Swain, Norman Wolmark
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background NSABP B-42 evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease-free after 5 years of aromatase inhibitor-based (AI) therapy. Seven-year results demonstrated a non-statistically significant t
Autor:
Niamh M. Keegan, Simon J. Furney, Janice M. Walshe, Giuseppe Gullo, M. John Kennedy, Diarmuid Smith, John McCaffrey, Catherine M. Kelly, Keith Egan, Jennifer Kerr, Mark Given, Peter O’Donovan, Andres Hernando, Ausra Teiserskiene, Imelda Parker, Elaine Kay, Angela Farrelly, Aoife Carr, Giulio Calzaferri, Ray McDermott, Maccon M. Keane, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Sinead Toomey, Bryan T. Hennessy
Publikováno v:
Cancers, Vol 13, Iss 6, p 1225 (2021)
Background: Activation of the phosphoinositide-3 kinase (PI3K) pathway is a resistance mechanism to anti-human epidermal growth factor receptor 2 (HER2) therapy. This phase Ib trial was conducted to determine the maximum tolerated dose (MTD) of copan
Externí odkaz:
https://doaj.org/article/866b588805c44d53b259bc41e6f9fa7e